HMGB1: A Promising Therapeutic Target for Prostate Cancer | Zendy

Gnanasekar Munirathinam | Zendy; Ramaswamy Kalyanasundaram | Zendy; Guoxing Zheng | Zendy; Aoshuang Chen | Zendy; Maarten C. Bosland | Zendy; André Kajdacsy-Balla | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

HMGB1: A Promising Therapeutic Target for Prostate Cancer

Author(s) -

Gnanasekar Munirathinam,

Ramaswamy Kalyanasundaram,

Guoxing Zheng,

Aoshuang Chen,

Maarten C. Bosland,

André Kajdacsy-Balla

Publication year - 2013

Publication title -

prostate cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.377

H-Index - 11

eISSN - 2090-3111

pISSN - 2090-312X

DOI - 10.1155/2013/157103

Subject(s) - hmgb1 , prostate cancer , medicine , angiogenesis , disease , cancer , metastasis , cancer research , prostate , bioinformatics , immunology , inflammation , biology

High mobility group box 1 (HMGB1) was originally discovered as a chromatin-binding protein several decades ago. It is now increasingly evident that HMGB1 plays a major role in several disease conditions such as atherosclerosis, diabetes, arthritis, sepsis, and cancer. It is intriguing how deregulation of HMGB1 can result in a myriad of disease conditions. Interestingly, HMGB1 is involved in cell proliferation, angiogenesis, and metastasis during cancer progression. Furthermore, HMGB1 has been demonstrated to exert intracellular and extracellular functions, activating key oncogenic signaling pathways. This paper focuses on the role of HMGB1 in prostate cancer development and highlights the potential of HMGB1 to serve as a key target for prostate cancer treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research